Adverse events possibly, probably, or definitely associated with protocol therapy
| Toxicity type . | Any grade . | Grade 1 . | Grade 2 . | Grade 3 . | Grade 4 . |
|---|---|---|---|---|---|
| Anemia | 3 (9.7%) | 0 (0%) | 2 (6.5%) | 1 (3.2%) | 0 (0%) |
| Arthralgia | 3 (9.7%) | 3 (9.7%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Azotemia | 3 (9.7%) | 1 (3.2%) | 2 (6.5%) | 0 (0%) | 0 (0%) |
| Cardiomyopathy | 1 (3.2%) | 0 (0%) | 0 (0%) | 1 (3.2%) | 0 (0%) |
| Chest pain (non-cardiac) | 1 (3.2%) | 0 (0%) | 1 (3.2%) | 0 (0%) | 0 (0%) |
| Dyspepsia | 1 (3.2%) | 1 (3.2%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Fatigue | 2 (6.5%) | 1 (3.2%) | 1 (3.2%) | 0 (0%) | 0 (0%) |
| Hyperglycemia | 31 (100%) | 7 (22.6%) | 17 (54.8%) | 7 (22.6%) | 0 (0%) |
| Hyperamylasemia | 8 (25.8%) | 7 (22.6%) | 1 (3.2%) | 0 (0%) | 0 (0%) |
| Hyperbilirubinemia | 9 (29.0%) | 7 (22.6%) | 2 (6.5%) | 0 (0%) | 0 (0%) |
| Hyperkalemia | 1 (3.2%) | 1 (3.2%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Hyperlipasemia | 17 (54.8%) | 4 (12.9%) | 8 (25.8%) | 5 (16.1%) | 0 (0%) |
| Hypokalemia | 1 (3.2%) | 1 (3.2%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Insomnia | 2 (6.5%) | 1 (3.2%) | 1 (3.2%) | 0 (0%) | 0 (0%) |
| Infusion reaction (rituximab) | 7 (22.6%) | 1 (3.2%) | 6 (19.4%) | 0 (0%) | 0 (0%) |
| Mucositis | 2 (3.2%) | 2 (3.2%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Neutropenia | 11 (34.8%) | 7 (22.6%) | 1 (3.2%) | 2 (6.5%) | 1 (3.2%) |
| Peripheral neuropathy | 6 (19.4%) | 5 (16.1%) | 1 (3.2%) | 0 (0%) | 0 (0%) |
| Rash | 9 (29.0%) | 6 (19.4%) | 3 (9.7%) | 0 (0%) | 0 (0%) |
| Thrombocytopenia | 1 (3.2%) | 1 (3.2%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Toxicity type . | Any grade . | Grade 1 . | Grade 2 . | Grade 3 . | Grade 4 . |
|---|---|---|---|---|---|
| Anemia | 3 (9.7%) | 0 (0%) | 2 (6.5%) | 1 (3.2%) | 0 (0%) |
| Arthralgia | 3 (9.7%) | 3 (9.7%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Azotemia | 3 (9.7%) | 1 (3.2%) | 2 (6.5%) | 0 (0%) | 0 (0%) |
| Cardiomyopathy | 1 (3.2%) | 0 (0%) | 0 (0%) | 1 (3.2%) | 0 (0%) |
| Chest pain (non-cardiac) | 1 (3.2%) | 0 (0%) | 1 (3.2%) | 0 (0%) | 0 (0%) |
| Dyspepsia | 1 (3.2%) | 1 (3.2%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Fatigue | 2 (6.5%) | 1 (3.2%) | 1 (3.2%) | 0 (0%) | 0 (0%) |
| Hyperglycemia | 31 (100%) | 7 (22.6%) | 17 (54.8%) | 7 (22.6%) | 0 (0%) |
| Hyperamylasemia | 8 (25.8%) | 7 (22.6%) | 1 (3.2%) | 0 (0%) | 0 (0%) |
| Hyperbilirubinemia | 9 (29.0%) | 7 (22.6%) | 2 (6.5%) | 0 (0%) | 0 (0%) |
| Hyperkalemia | 1 (3.2%) | 1 (3.2%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Hyperlipasemia | 17 (54.8%) | 4 (12.9%) | 8 (25.8%) | 5 (16.1%) | 0 (0%) |
| Hypokalemia | 1 (3.2%) | 1 (3.2%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Insomnia | 2 (6.5%) | 1 (3.2%) | 1 (3.2%) | 0 (0%) | 0 (0%) |
| Infusion reaction (rituximab) | 7 (22.6%) | 1 (3.2%) | 6 (19.4%) | 0 (0%) | 0 (0%) |
| Mucositis | 2 (3.2%) | 2 (3.2%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Neutropenia | 11 (34.8%) | 7 (22.6%) | 1 (3.2%) | 2 (6.5%) | 1 (3.2%) |
| Peripheral neuropathy | 6 (19.4%) | 5 (16.1%) | 1 (3.2%) | 0 (0%) | 0 (0%) |
| Rash | 9 (29.0%) | 6 (19.4%) | 3 (9.7%) | 0 (0%) | 0 (0%) |
| Thrombocytopenia | 1 (3.2%) | 1 (3.2%) | 0 (0%) | 0 (0%) | 0 (0%) |
Numbers given as number (percentage) of events.